5 Topics
|
|
I really don’t write enough about the biopharmaceutical market, which in tough economic times, can be a good defensive play relative to the rest of the market – even when compared to uniform technology stocks. My reasoning is simple. We have illness, disease, and injury in good economic times and … |
|
Both the Dow and the Nasdaq are flirting with positive territory today, thanks in part to one biotechnology stalwart, Amgen, which is up three points in trading. Why? Well, the Street is getting excited about life sciences stocks again, as several research reports hit the street suggesting that the biopharm … |
|
At the end of trading today (Friday) it looks like the stock market won't end up in positive territory, but it will come close - an event every trader and investor on the planet planet will take in a Wall Street minute. No rhyme or reason why, it just seems … |
|
Investors are in survival mode right now, just trying to hang on in a market that has given away much of this year's gains. Key culprits are the ongoing credit crisis, which has banks and lenders reeling under the weight of billion dollar losses (hello, Wachovia) and from a weak … |
|
It’s back. The dot.com bubble, that is. And with it comes a new wave of venture capitalists that are pouring money not just into Internet companies, but in life sciences companies, as well. And in increasingly larger numbers. An October article in The New York Times says it all. “Internet … |
The End.